Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study

Vasoconstriction and anti-inflammatory properties of the selective α-adrenergic receptor agonist brimonidine

(2014) David Piwnica et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

The psychological impact of rosacea and the influence of current management options

(2014) Farah Moustafa et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Treatment of facial erythema in patients with rosacea with topical brimonidine tartrate: correlation of patient satisfaction with standard clinical endpoints of improvement of facial erythema

(2014) J. Fowler et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Rosacea: Current state of epidemiology

(2013) Jerry Tan et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Clinical presentations and classification of rosacea

(2011) T. Jansen   ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE

Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies

(2011) J. Fowler et al.   BRITISH JOURNAL OF DERMATOLOGY

The impact of rosacea on quality of life: effects of demographic and clinical characteristics and various treatment modalities

(2010) B. Aksoy et al.   BRITISH JOURNAL OF DERMATOLOGY

Subjective Disease Perception and Symptoms of Depression in Relation to Healthcare-seeking Behaviour in Patients with Rosacea

(2009) K Abram et al.   ACTA DERMATO-VENEREOLOGICA